MitoQ

Researchers identify top target for senolytic drugs

Latest articles

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

New SIRT6 activator supplement hits the market

Sirtuin 6, the protein making waves in the longevity pool, can now be activated by a brand-new supplement. SIRT6 is a protein with an important...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...
MitoQ

Click the globe for translations.

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs.

Cellular senescence is the very definition of killing with kindness; when a cell realises it should stop dividing because it’s reached the division limit (the Hayflick Limit), or has developed a cancerous mutation that could lead to runaway multiplication and become a tumour, it becomes senescent. Damage can also trigger senescence, which alerts the body to the harm.

Longevity.Technology: Like purgatory, senescence should be a transitional state, a stop on the way to death, as the self-destruct countdown to apoptosis (cell death) should start when cellular senescent begins. However, this doesn’t always happen and the cell remains in permanent limbo, not dividing, growing or being useful, but hanging around, encouraging other cells into senescence and also pumping out a harmful cocktail of proteins and other damaging chemicals.

This toxic excretion can damage other cells, causing inflammation, aging and cell death and driving most age-related diseases, such as arthritis, cardiovascular disease and diabetes. Research into senolytics and senotherapeutics is trying to find ways of tacking cellular senescence.

University of Minnesota Medical School researchers found that senescent immune cells are the most dangerous type of senescent cell. The research was published in Nature.

The research team — led by Dr Laura Niedernhofer, MD, PhD, a professor in the Department of Biochemistry, Molecular Biology and Biophysics — discovered that senescent immune cells drive tissue damage all over the body and shorten lifespan. Therefore, senescent immune cells are particularly detrimental and should be a top target for senolytic therapy.


 

“Now that we have identified which cell type is most deleterious, this work will steer us towards developing senolytics that target senescent immune cells,”

 


 

U of M researchers, including Niedernhofer and collaborators at the Mayo Clinic, previously identified this new class of drugs back in 2015, coining the term senolytics; these drugs , which selectively remove senescent cells from the body. However, senolytic drugs must be targeted towards a specific cell type, so a senolytic drug that can kill senescent brain cells is no good against senescent liver cells.

The U of M defined the contribution of immune system aging to organism aging by selectively deleted Ercc1, a gene which encodes a crucial DNA repair protein in mouse haematopoietic cells (the cells that form blood and immune cells). This deletion had the effect of increasing the amount of endogenous DNA damage (damage caused by reactive oxygen species or metabolic processes) and therefore the number of cells becoming senescent.

The mice in the experiment were healthy into adulthood, but then displayed premature onset of immunosenescence characterised by attrition and senescence of specific immune cell populations; they also demonstrated impaired immune function, similar to changes that occur during aging in mice in the wild [2].

“Now that we have identified which cell type is most deleterious, this work will steer us towards developing senolytics that target senescent immune cells,” said Niedernhofer, who is also the director for the Institute on the Biology of Aging and Metabolism at the U of M Medical School, one of the state-sponsored Medical Discovery Teams.

“We also hope that it will help guide discovery of biomarkers in immune cell populations that will help gauge who is at risk of tissue damage and rapid aging, and therefore who is at most need of senolytic therapy [1].”

We are currently preparing our market intelligence report on senotherapeutics which is available for pre-order.

[1] https://med.umn.edu/news-events/u-m-medical-school-researchers-identify-target-senolytic-drugs
[2] https://www.nature.com/articles/s41586-021-03547-7

Image courtesy of the University of Minnesota

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

Brinter accelerates 3D bioprinting with €1.2m seed fund

Modular multi-material 3D bioprinting solution hopes to develop cost-effective answer to global need for kidney transplants. Turku-based bioprinting start-up Brinter has today announced the successful closure...

Occuity – shining a light on health and longevity

Forget windows to the soul, Occuity's non-invasive smart diagnostic tech provides a window to health and wellness. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited)...

Biogen wins FDA approval for Alzheimer’s drug aducanumab

Landmark decision means Alzheimer's research is moving past a bottleneck, with first new drug in 18 years. After two years of back-and-forth, the FDA has...

Research increases mice life expectancy by 30%

Bar-Ilan University researchers increase life expectancy in mice with protein SIRT6. The "fountain of youth" allows old mice to conduct the same level of...
Supps report ad middle